Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Sees Large Increase in Short Interest

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 38,400 shares, an increase of 58.0% from the March 31st total of 24,300 shares. Currently, 3.2% of the company’s shares are short sold. Based on an average daily volume of 49,500 shares, the short-interest ratio is currently 0.8 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals in a research report on Wednesday. They set a “hold” rating for the company.

Cyclacel Pharmaceuticals Trading Down 5.6 %

Cyclacel Pharmaceuticals stock opened at $1.51 on Friday. The firm has a 50 day moving average price of $2.29 and a 200 day moving average price of $3.84. Cyclacel Pharmaceuticals has a fifty-two week low of $1.41 and a fifty-two week high of $13.20.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million for the quarter. As a group, equities research analysts anticipate that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current fiscal year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.